Sarda Proteins Q1 Results FY27: Company Swings to Rs 1 Crore Profit as Revenue Grows 18.61%
- July 16, 2026
- Posted by: Ankit Jaiswal
- Category: News
Sarda Proteins Q1 FY27: revenue Rs 12 Cr, up 18.61% YoY. Net profit Rs 1 Cr, versus a loss of Rs 0.49 Cr a year ago. Gross loss narrowed. Stock at Rs 97.78, up 4.99% on 15 July 2026.
Sarda Proteins Q1 results FY27 were announced on Wednesday, 15 July 2026, with the edible oils and agri commodities trading company reporting revenue of Rs 12 crore for the quarter ended 30 June 2026, up 18.61% from Rs 10 crore in the year ago quarter. The company swung to a net profit of around Rs 1 crore in the Sarda Proteins Q1 results FY27, compared with a loss of Rs 0.49 crore in Q1 FY26, while gross profit also turned sharply positive.
Shares of Sarda Proteins rose 4.99% to close at Rs 97.78, with the market responding positively to both the healthy revenue growth and the swing back into profitability for this edible oils and agri commodities trader.
Click Here – Get Free Investment Predictions
Sarda Proteins Q1 results FY27 Financial Highlights
The June quarter marked a clear turnaround, with growing revenue and a swing to profitability, a combination central to the Sarda Proteins Q1 results FY27. The table below summarises the standalone numbers against the year ago quarter, in rounded crore terms.
| Metric | Q1 FY27 | Q1 FY26 | YoY Change |
|---|---|---|---|
| Revenue | Rs 12 Cr | Rs 10 Cr | +18.61% |
| Gross Profit / (Loss) | -Rs 3 Cr | -Rs 0.49 Cr | Loss widened |
| Net Profit / (Loss) | Rs 1 Cr | -Rs 0.49 Cr | Turned positive, +436.38% |
Net profit swinging to positive territory in the Sarda Proteins Q1 results FY27 despite gross loss actually widening suggests other income, likely from the company’s trading and investment activities, played a significant role in the bottom line turnaround this quarter.
Sarda Proteins Q1 results FY27 Performance Analysis
Get Personalised Guidance from a SEBI-Registered Investment Advisor
The most important nuance in the Sarda Proteins Q1 results FY27 is that net profit turned positive even as gross loss widened, indicating that other income rather than core trading operations drove the swing to profitability this quarter, a distinction investors should keep in mind when assessing sustainability.
As a company engaged in wholesale trading of edible oils and agricultural commodities such as mustard oil, refined oil, and various seeds, Sarda Proteins’ revenue can be volatile given the thin margins and price fluctuations typical of commodity trading businesses.
Revenue growth of 18.61% in the Sarda Proteins Q1 results FY27 reflects healthy volume growth in the company’s core edible oil and agri commodity trading business, even as the widening gross loss suggests trading spreads remained under some pressure during the quarter.
Sarda Proteins Q1 results FY27: Key Business Factors
1. Edible Oil and Agri Commodity Trading
As a trader of edible oils, mustard oil, seeds and other agricultural commodities, the revenue growth reflected in the Sarda Proteins Q1 results FY27 points to healthy volume trends in this thin-margin business.
2. Other Income Supporting the Turnaround
With gross loss actually widening even as net profit turned positive, other income appears to have played the decisive role in this quarter’s swing to profitability.
3. Thin Trading Margins
The nature of commodity trading means margins can be structurally thin and volatile, a dynamic reflected in the widening gross loss even as the Sarda Proteins Q1 results FY27 show an improving net profit picture.
Dividend Details
No dividend was announced along with the Sarda Proteins Q1 results FY27. Given the company’s small scale and the volatile nature of commodity trading margins, retaining any available capital for working capital needs is the more likely near-term approach.
Sarda Proteins Q1 results FY27 Outlook for the Full Year
Whether the company can improve its core trading margins, which remained under pressure this quarter despite the net profit turnaround, will be an important factor to track into the September quarter. Investors should watch for whether gross profitability improves alongside continued revenue growth in the edible oil and agri commodities trading business.
Sarda Proteins Stock Performance After the Q1 Results
Download the Univest iOS App or Univest Android App to track Sarda Proteins live share price and upcoming quarterly results.
Sarda Proteins share price rose 4.99% to close at Rs 97.78 after the Sarda Proteins Q1 results FY27, with the market responding positively to the swing back into net profitability.
As a small cap stock in the agri commodities trading space, the counter can see sharp price swings on quarterly results, and investors should factor in relatively lower trading liquidity when sizing positions.
Key Risks
Investors going through the fine print of the Sarda Proteins Q1 results FY27 should also weigh the following risks.
1. Widening Gross Loss Despite Net Profit
The core trading business behind the Sarda Proteins Q1 results FY27 actually showed a wider gross loss this quarter, meaning the net profit turnaround depended on other income rather than improving core operations.
2. Thin and Volatile Trading Margins
Edible oil and agri commodity trading is inherently a thin-margin business exposed to commodity price volatility, which can swing profitability sharply from quarter to quarter.
3. Small Cap Liquidity and Governance
As a small cap trading company, investors should apply appropriate scrutiny to disclosures and governance practices given the historically volatile nature of the business.
Conclusion
Sarda Proteins Q1 results FY27 show revenue up 18.61% to Rs 12 crore and a swing to a Rs 1 crore net profit from a loss a year ago, though the widening gross loss suggests other income rather than core trading operations drove the improvement. The revenue growth is the positive underlying signal in the Sarda Proteins Q1 results FY27, against continued pressure on core trading margins. Investors should treat this as a high risk situation and consult a SEBI-registered advisor before acting on the numbers.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Sarda Proteins Q1 results FY27
When were the Sarda Proteins Q1 results FY27 announced?
Ans. The Sarda Proteins Q1 results FY27 were announced on Wednesday, 15 July 2026, for the quarter ended 30 June 2026.
What was the revenue in Sarda Proteins Q1 results FY27?
Ans. Revenue in the Sarda Proteins Q1 results FY27 grew 18.61% year on year to Rs 12 crore from Rs 10 crore.
Did Sarda Proteins turn profitable in Q1 FY27?
Ans. Yes. The Sarda Proteins Q1 results FY27 show the company swinging to a net profit of around Rs 1 crore, compared with a loss of Rs 0.49 crore in Q1 FY26, though gross loss actually widened.
What does Sarda Proteins do as a company?
Ans. Sarda Proteins is engaged in the wholesale trading of edible oils and agricultural commodities in India, including mustard oil, refined oil, mustard seeds and guar seeds.
How did Sarda Proteins share price react to the Q1 results FY27?
Ans. Sarda Proteins share price rose 4.99% to close at Rs 97.78 after the Sarda Proteins Q1 results FY27.
Is Sarda Proteins a good buy after the Q1 results FY27?
Ans. The Sarda Proteins Q1 results FY27 show revenue growth and a net profit turnaround, though the widening gross loss suggests core trading margins remain under pressure. This article is for educational purposes only. Consult a SEBI-registered advisor before investing.
